<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24981311</article-id><article-id pub-id-type="pmc">4094395</article-id><article-id pub-id-type="publisher-id">1471-2407-14-476</article-id><article-id pub-id-type="doi">10.1186/1471-2407-14-476</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>VEGFR-3 and CXCR4 as predictive markers for treatment with fluorouracil, leucovorin plus either oxaliplatin or cisplatin in patients with advanced esophagogastric cancer: a comparative study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Thomaidis</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>thomas.thomaidis@unimedizin-mainz.de</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Maderer</surname><given-names>Annett</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>annett.maderer@unimedizin-mainz.de</email></contrib><contrib contrib-type="author" id="A3"><name><surname>Al-Batran</surname><given-names>Salah-Eddin</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>albatran@aol.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Kany</surname><given-names>Janis</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jakany@web.de</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Pauligk</surname><given-names>Claudia</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>pauligk.claudia@khnw.de</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Steinmetz</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>steinmetz.kristina@khnw.de</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Schad</surname><given-names>Arno</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>arno.schad@unimedizin-mainz.de</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Hofheinz</surname><given-names>Ralf</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>ralf.hofheinz@umm.de</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Schmalenberg</surname><given-names>Harald</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>Harald.Schmalenberg@med.uni-jena.de</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Homann</surname><given-names>Nils</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>nils.homann@klinikum.wolfsburg.de</email></contrib><contrib contrib-type="author" id="A11"><name><surname>Galle</surname><given-names>Peter Robert</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>galle@mail.uni-maniz.de</email></contrib><contrib contrib-type="author" corresp="yes" id="A12"><name><surname>Moehler</surname><given-names>Markus</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>moehler@mail.uni-mainz.de</email></contrib></contrib-group><aff id="I1"><label>1</label>I. Medical Department, Johannes-Gutenberg University of Mainz, Langenbeckstr.1, 55131 Mainz, Germany</aff><aff id="I2"><label>2</label>Institute of Clinical- Oncological Research at Krankenhaus Nordwest, UCT University Cancer Center, Frankfurt am Main, Germany</aff><aff id="I3"><label>3</label>III. Medical Clinic, University Clinic, Mannheim, Germany</aff><aff id="I4"><label>4</label>Tumor centre, University of Jena, Jena, Germany</aff><aff id="I5"><label>5</label>II. Medical Clinic, Wolfsburg, Germany</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>1</day><month>7</month><year>2014</year></pub-date><volume>14</volume><fpage>476</fpage><lpage>476</lpage><history><date date-type="received"><day>17</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>18</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Thomaidis et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Thomaidis et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri xlink:href="http://www.biomedcentral.com/1471-2407/14/476"/><abstract><sec><title>Background</title><p>Combination of fluoropyrimidines and a platinum derivative are currently standards for systemic chemotherapy in advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ). Nevertheless, individual likelihood for response to these therapeutic regimes remains uncertain. Even more, no predictive markers are available to determine which patients may benefit more from oxaliplatin versus cisplatin or vice versa. The new invasion and stem cell markers VEGFR-3 and CXCR4 have been linked prognostically with more aggressive esophagogastric cancer types. Thus, we aimed to assess correlations of VEGFR-3 and CXCR4 expression levels with clinical outcome in a randomized phase III study of patients with oxaliplatin/leucovorin/5-FU (FLO) versus cisplatin/leucovorin/5-FU (FLP).</p></sec><sec><title>Methods</title><p>The patients data examined in this study (n&#x02009;=&#x02009;72) were from the collective of the FLO vs. FLP phase III AIO trial. Tumour tissues were stained via immunohistochemistry for VEGFR-3 and CXCR4 expression and results were evaluated by two independent, blinded investigators.</p><p>Outcome parameter: Survival analysis was calculated for patients receiving FLO vs. FLP in relation to VEGFR-3 and CXCR4 expression.</p></sec><sec><title>Results</title><p>54% and 36% of the examined tumour tissues showed strong positive expression of VEGFR-3 and CXCR4 respectively. No superiority of each regime was detected in terms of overall survival (OS) in the whole population. Patients with strong expression of CXCR4 on their tumour tissues profited more in terms of OS under the treatment of FLP (mOS: 28 vs 15&#x000a0;months, p&#x02009;=&#x02009;0.05 respectively). Patients with negative VEGFR-3 and CXCR4 expression had a trend to live longer when FLO regime was applied (mOS: 22 vs. 9&#x000a0;months, p&#x02009;=&#x02009;0.099 and 20 vs. 10&#x000a0;months, p&#x02009;=&#x02009;0.073 respectively). In an exploratory analysis of patients older than 60&#x000a0;years at diagnosis, we observed a significant benefit in overall survival for VEGFR-3 and CXCR4-positive patients when treated with FLP (p&#x02009;=&#x02009;0.002, p&#x02009;=&#x02009;0.021 respectively).</p></sec><sec><title>Conclusions</title><p>CXCR4 positive patients profited in terms of OS from FLP, whereas FLO proved to be more effective in CXCR4 and VEGFR-3 negative patients. Our results suggest, despite the limited size of the study, a predictive value of these biomarkers concerning chemotherapy with FLP or FLO in advanced esophagogastric cancer.</p></sec></abstract><kwd-group><kwd>VEGFR-3</kwd><kwd>CXCR4</kwd><kwd>Advanced esophagogastric cancer</kwd><kwd>FLO</kwd><kwd>FLP</kwd><kwd>Biomarkers</kwd></kwd-group></article-meta></front><body><sec><title>Background</title><p>Adenocarcinoma of the stomach and the gastroesophageal junction (GEJ) is one of the most common and lethal malignancies with approximately 990,000 new cases and 738,000 deaths per year worldwide [<xref ref-type="bibr" rid="B1">1</xref>]. Most gastric cancers are unfortunately diagnosed at an advanced stage, so that even after a potential curative gastrectomy relapse rates remain at levels of between 40% and 60% [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>Systemic chemotherapy is nowadays the gold standard for the palliative treatment of patients with advanced or metastatic cancer of the stomach or GEJ. The combination of fluoropyrimidine and platinum is widely considered to be the treatment of choice in advanced gastric cancers having shown a benefit in overall survival (OS) and progression free survival (PFS) in different studies [<xref ref-type="bibr" rid="B3">3</xref>-<xref ref-type="bibr" rid="B5">5</xref>]. Nevertheless, the focus of recent and current studies remains the identification of a superior treatment combination while minimizing toxicity.</p><p>To the best of our knowledge, there are two phase III studies that deal with the effect and toxicity of oxaliplatin compared with cisplatin in the treatment of metastatic esophagogastric cancer [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>]. Data from the REAL-2 trial [<xref ref-type="bibr" rid="B6">6</xref>] showed no inferiority of oxaliplatin versus cisplatin or of capecitabine versus 5-FU for treatment in this category of patients. Moreover in a post-hoc subgroup analysis oxaliplatin proved to be more effective than cisplatin in patients &#x0003e;65&#x000a0;years [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In the search of new biomarkers for advanced esophagogastric carcinoma, VEGFR-3 and CXCR4 have recently become the focus of research [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. VEGFR-3 has been associated with lymphangiogenesis, invasion and metastasis of gastric cancer [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B21">21</xref>] whilst CXCR4 is associated with stimulation of angiogenesis, lymph node metastasis and peritoneal carcinomatosis [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B22">22</xref>-<xref ref-type="bibr" rid="B26">26</xref>]. Nevertheless, their role as predictive markers or as potential therapeutic targets in advanced esophagogastric cancer remains unclear. Despite the encouraging results of the addition of bevacizumab in phase II trials in metastatic and loco regional esophagogastric cancer [<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>], a significant benefit in terms of OS was not observed in the phase III AVAGAST trial [<xref ref-type="bibr" rid="B29">29</xref>]. Furthermore, there are to date no comparative studies that focus on a correlation of VEGFR-3 and CXCR4 with the clinical outcome using different therapeutic regimes in patients with locally advanced or metastatic adenocarcinoma of the stomach or GEJ.</p><p>The aim of this study was to investigate whether VEGFR-3 and CXCR4 could serve as molecular patterns for personalisation of standard chemotherapy in patients with advanced esophagogastric cancer. We therefore examined and compared the effect of combined chemotherapy with oxaliplatin/leucovorin/5-FU (FLO) versus cisplatin/leucovorin/5-FU (FLP) in patients with advanced esophagogastric cancer in relation to tumour VEGFR-3 and CXCR4 expression.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients</title><p>The patient data examined in this study (n&#x02009;=&#x02009;72) originate from the collective of the FLO vs. FLP Phase III trial of the AIO. A comparison of the main disease characteristics between patients in our study and the overall trial population is shown in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>. Patients were recruited in 31 German and one Swiss centre in a time period of 3&#x000a0;years. Eligibility criteria were histological confirmation of locally advanced or metastatic adenocarcinoma of the stomach or GEJ. Patients had to be over 18&#x000a0;years old, have not received any prior palliative chemotherapy, have not suffered from another type of cancer in the previous five years and have a creatinine clearance&#x02009;&#x0003e;&#x02009;50&#x000a0;ml/min and adequate bone marrow function. Patients gave written informed consent according to the Helsinki protocol before entering the study, which was approved by the ethics committees of the participating institutions and the Federal Institute for Drugs and Medical Devices (Ref. Nr: 4020513).</p></sec><sec><title>Treatment</title><p>The participants were randomized into two treatment arms. The FLO-group received infusional oxaliplatin 85&#x000a0;mg/m<sup>2</sup> and leucovorin 200&#x000a0;mg/m<sup>2</sup> over 2&#x000a0;hours every 2&#x000a0;weeks, followed by an infusion of 5-FU 2600&#x000a0;mg/m<sup>2</sup> over 24&#x000a0;hours. Patients in the FLP therapy arm received cisplatin 50&#x000a0;mg/m<sup>2</sup> every 2&#x000a0;weeks, combined with the weekly infusion of leucovorin 200&#x000a0;mg/m<sup>2</sup> over 2&#x000a0;hours and FU 2000&#x000a0;mg/m<sup>2</sup> over 24&#x000a0;hours. After 6&#x000a0;weeks, the FLP-treatment was followed by a 2-week rest period.</p></sec><sec><title>Immunohistochemistry</title><p>The expression of VEGFR-3 and CXCR4 was analyzed by immunohistochemistry (IHC). Paraffin-embedded tissue samples were obtained from 70 patients for CXCR4 and 69 for VEGFR-3, due to limited availability of material. The nature of the collected material was mainly tumour resections.</p><p>Three micrometer thick tissue sections were cut and mounted on super frost slides. These were deparaffinized, rehydrated and peroxidase blocked (3% H<sub>2</sub>O<sub>2</sub> in methanol, 30&#x000a0;min). After blocking of nonspecific protein binding sites by using fresh frozen plasma (30&#x000a0;min) slides were incubated with the respective primary antibody VEGFR-3 (sc 321, Santa Cruz Biotechnology, UK, 1:200, 2&#x000a0;h) and CXCR4 (CIO115, Capralogics, USA, 1:300, 1.5&#x000a0;h) at room temperature, as described before [<xref ref-type="bibr" rid="B30">30</xref>-<xref ref-type="bibr" rid="B32">32</xref>]. Incubation with secondary antibody (anti-rabbit&#x02013;mouse&#x02013;goat antibody) was followed by incubation with streptavidin&#x02013;POD (DAKO, Germany, each 15&#x000a0;min). Specific antibody binding was visualized using DAB solution (DAKO, Germany) and the tissues were counterstained by hemalaun solution (DAKO, Germany). Between each step of staining the specimens were washed in distilled water or DPBS.</p><p>Evaluation of staining was performed by two independent, blinded pathologists.</p></sec><sec><title>Statistical analysis</title><p>The staining was evaluated by intensity (no staining 0, weak 1, moderate 2, and strong 3) and the extent of the stained tumour area (0% 0, &#x0003c;25% 1, 25-50% 2, 50-75% 3, &#x0003e; 75% 4). These two classifications were added together and divided into the categories negative and positive. Up to a total of 5, staining was scored as negative, from 6 or more it was considered clearly positive. All statistical analyses were done by using MedCalc software 2013 in close cooperation with the IMBEI. The survival analysis was performed by using the Kaplan-Meier method and the log rank test. To investigate the association between the results of immunohistochemistry obtained for VEGFR-3 and CXCR4 and clinical-pathological parameters, univariate statistical analysis were performed using Pearson's Chi-2 test or Fisher's exact test. p values&#x02009;&#x0003c;&#x02009;0.05 were considered to indicate significant differences.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Patients characteristics</title><p>The average age of patients was 59.8&#x000a0;years and ranged from 33 to 84&#x000a0;years, two thirds of the patients were male. There were no major differences concerning the main disease characteristics in comparison to the overall phase III trial, see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>. In the statistical analysis of VEGF receptor 3 (VEGFR-3), a total of 69 tumour specimens were included. The cut-off for positive VEGFR-3 expression was drawn at a value of 6, which was true for 39 specimens (54%). 36 patients were treated with FLO, 33 patients received FLP (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>). In the statistical analysis of CXCR4, tissue samples from 70 patients were included. 37 of these patients received the FLO regimen, 33 were treated with FLP. The cut-off for a positive detection was set at 6 as sum of the scores for proportion and intensity of staining (Figure&#x000a0;<xref ref-type="fig" rid="F1">1</xref>). In 26 (36%) of all tissue samples, a strong CXCR4 expression could be detected.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Characteristic</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>All (stained)</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>FLO</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>FLP</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>VEGFR-3 +</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>VEGFR-3 -</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>CXCR4 +</bold><hr/></th><th colspan="2" align="left" valign="bottom"><bold>CXCR4 -</bold><hr/></th></tr><tr><th align="left">&#x000a0;</th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th><th colspan="2" align="left"><bold>n</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>Number</bold><hr/></td><td colspan="2" align="left" valign="bottom">72<hr/></td><td colspan="2" align="left" valign="bottom">38<hr/></td><td colspan="2" align="left" valign="bottom">34<hr/></td><td colspan="2" align="left" valign="bottom">39<hr/></td><td colspan="2" align="left" valign="bottom">30<hr/></td><td colspan="2" align="left" valign="bottom">26<hr/></td><td colspan="2" align="left" valign="bottom">44<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Age (years)</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom"><bold>SD +/&#x02212;</bold><hr/></td></tr><tr><td align="left" valign="bottom"><bold>Mean</bold><hr/></td><td align="left" valign="bottom">59.8<hr/></td><td align="left" valign="bottom">12.04<hr/></td><td align="left" valign="bottom">59.7<hr/></td><td align="left" valign="bottom">12.76<hr/></td><td align="left" valign="bottom">59.9<hr/></td><td align="left" valign="bottom">11.39<hr/></td><td align="left" valign="bottom">62.4<hr/></td><td align="left" valign="bottom">12.33<hr/></td><td align="left" valign="bottom">55.6<hr/></td><td align="left" valign="bottom">10.8<hr/></td><td align="left" valign="bottom">59<hr/></td><td align="left" valign="bottom">12.6<hr/></td><td align="left" valign="bottom">60<hr/></td><td align="left" valign="bottom">11.95<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Range</bold><hr/></td><td colspan="2" align="left" valign="bottom">33.1-84.2<hr/></td><td colspan="2" align="left" valign="bottom">33.1-84.2<hr/></td><td colspan="2" align="left" valign="bottom">34.7-78.9<hr/></td><td colspan="2" align="left" valign="bottom">34.7-84.2<hr/></td><td colspan="2" align="left" valign="bottom">33.1-78.9<hr/></td><td colspan="2" align="left" valign="bottom">33.1-84.2<hr/></td><td colspan="2" align="left" valign="bottom">34.7-78.9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Gender</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">%<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Male</bold><hr/></td><td align="left" valign="bottom">48<hr/></td><td align="left" valign="bottom">66.7<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">50<hr/></td><td align="left" valign="bottom">29<hr/></td><td align="left" valign="bottom">85.3<hr/></td><td align="left" valign="bottom">26<hr/></td><td align="left" valign="bottom">66.7<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">63.3<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">73.1<hr/></td><td align="left" valign="bottom">28<hr/></td><td align="left" valign="bottom">63.6<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Female</bold><hr/></td><td align="left" valign="bottom">24<hr/></td><td align="left" valign="bottom">33.3<hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">50<hr/></td><td align="left" valign="bottom">5<hr/></td><td align="left" valign="bottom">14.7<hr/></td><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">33.3<hr/></td><td align="left" valign="bottom">11<hr/></td><td align="left" valign="bottom">36.7<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">26.9<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">36.4<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Primary</bold><hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Cardia</bold><hr/></td><td align="left" valign="bottom">19<hr/></td><td align="left" valign="bottom">26.4<hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">26.3<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">27.3<hr/></td><td align="left" valign="bottom">10<hr/></td><td align="left" valign="bottom">25.6<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">24.1<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">23.1<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">27.9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Corpus</bold><hr/></td><td align="left" valign="bottom">27<hr/></td><td align="left" valign="bottom">37.5<hr/></td><td align="left" valign="bottom">15<hr/></td><td align="left" valign="bottom">39.5<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">36.4<hr/></td><td align="left" valign="bottom">14<hr/></td><td align="left" valign="bottom">35.9<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">41.4<hr/></td><td align="left" valign="bottom">12<hr/></td><td align="left" valign="bottom">46.2<hr/></td><td align="left" valign="bottom">15<hr/></td><td align="left" valign="bottom">34.9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Antrum</bold><hr/></td><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">18.1<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">18.4<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">18.2<hr/></td><td align="left" valign="bottom">7<hr/></td><td align="left" valign="bottom">17.9<hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">20.7<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">15.4<hr/></td><td align="left" valign="bottom">9<hr/></td><td align="left" valign="bottom">20.9<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Esophagus</bold><hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">2.8<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">2.6<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">3<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">5.1<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">0<hr/></td><td align="left" valign="bottom">1<hr/></td><td align="left" valign="bottom">2.3<hr/></td></tr><tr><td align="left" valign="bottom"><bold>Stomach</bold><hr/></td><td align="left" valign="bottom">6<hr/></td><td align="left" valign="bottom">8.3<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">5.3<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">12.1<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">10.3<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">6.9<hr/></td><td align="left" valign="bottom">2<hr/></td><td align="left" valign="bottom">7.7<hr/></td><td align="left" valign="bottom">4<hr/></td><td align="left" valign="bottom">9.3<hr/></td></tr><tr><td align="left"><bold>No information</bold></td><td align="left">4</td><td align="left">5.6</td><td align="left">3</td><td align="left">7.9</td><td align="left">1</td><td align="left">3</td><td align="left">2</td><td align="left">5.1</td><td align="left">2</td><td align="left">6.9</td><td align="left">2</td><td align="left">7.7</td><td align="left">2</td><td align="left">4.7</td></tr></tbody></table></table-wrap><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Immunohistochemistry for VEGFR-3 and CXCR-4 in tumour tissues obtained from patients with esophagogastric adenocarcinoma. A</bold>. strong positive staining (&#x0003e;5) for VEGFR-3, <bold>B</bold>. strong positive staining (&#x0003e;5) for CXCR4 (black arrows).</p></caption><graphic xlink:href="1471-2407-14-476-1"/></fig><p>There was an equal distribution of the patients in regards of treatment and positivity of markers (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). Location of the primary and age showed no statistical significant changes within all groups (Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Distribution of patients&#x02019; treatment in relation to expression of VEGFR-3 or CXCR4</p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left" valign="bottom"><bold>Characteristic</bold><hr/></th><th align="left" valign="bottom"><bold>FLO</bold><hr/></th><th align="left" valign="bottom">&#x000a0;<hr/></th><th align="left" valign="bottom"><bold>FLP</bold><hr/></th><th align="left" valign="bottom">&#x000a0;<hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th><th align="left"><bold>n</bold></th><th align="left"><bold>%</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom"><bold>VEGFR-3 +</bold><hr/></td><td align="left" valign="bottom">22<hr/></td><td align="left" valign="bottom">56.4<hr/></td><td align="left" valign="bottom">17<hr/></td><td align="left" valign="bottom">43.6<hr/></td></tr><tr><td align="left" valign="bottom"><bold>VEGFR-3 -</bold><hr/></td><td align="left" valign="bottom">14<hr/></td><td align="left" valign="bottom">46.7<hr/></td><td align="left" valign="bottom">16<hr/></td><td align="left" valign="bottom">53.3<hr/></td></tr><tr><td align="left" valign="bottom"><bold>CXCR4 +</bold><hr/></td><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">50<hr/></td><td align="left" valign="bottom">13<hr/></td><td align="left" valign="bottom">50<hr/></td></tr><tr><td align="left"><bold>CXCR4 -</bold></td><td align="left">24</td><td align="left">54.5</td><td align="left">20</td><td align="left">45.5</td></tr></tbody></table></table-wrap></sec><sec><title>General statistical analysis</title><p>In terms of efficacy, no difference in the response to the treatment regimens FLO and FLP could be detected (p&#x02009;=&#x02009;0.839). Furthermore, there was no significant difference in survival between VEGFR-3 positive and negative patients or for CXCR4 expression (data not shown).</p></sec><sec><title>Results for the VEGF receptor 3</title><p>The response to either therapy regimen strongly depended on the expression status of VEGFR-3. Patients with a negative VEGFR-3 state significantly benefited from treatment with FLO in survival over 18&#x000a0;months (p&#x02009;=&#x02009;0.026). A strong trend in favour of the FLO-therapy was detected (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>A, p&#x02009;=&#x02009;0.099), in terms of 5-year survival. The median survival for VEGFR-3 negative patients was 22&#x000a0;months in FLO, compared to 9&#x000a0;months in the FLP arm and was statistically significant. Patients with positive VEGFR-3 status had a median survival benefit of 5&#x000a0;months under FLP treatment (21&#x000a0;months under FLP vs. 16&#x000a0;months under FLO). In the 5-year survival, a trend in favour of the FLP-therapy group was found for patients with strong expression of VEGFR-3 (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>B, p&#x02009;=&#x02009;0.227).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p><bold>Survival analysis in patients treated with FLO versus FLP in relation to the expression of VEGFR-3. A</bold>. VEGFR-3 negative in observation time of 5&#x000a0;years. <bold>B</bold>. VEGFR-3 positive in observation time of 60&#x000a0;months.</p></caption><graphic xlink:href="1471-2407-14-476-2"/></fig></sec><sec><title>Results for the CXC receptor 4</title><p>The CXCR4 expression in tumour tissues showed a strong impact on survival in both treatment groups FLO and FLP. While CXCR4 negative patients showed a trend towards treatment benefit with FLO (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>A, p&#x02009;=&#x02009;0.073), patients with strong CXCR expression survived longer under FLP treatment (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>B, p&#x02009;=&#x02009;0.05). The median survival of patients with negative CXCR4-status was a statistic relevant 10&#x000a0;months longer under FLO than FLP (20 vs. 10&#x000a0;months), while strong CXCR4 expression was associated with a statistically significant median survival benefit of 13&#x000a0;months for FLP compared with FLO (28 vs. 15&#x000a0;months, p&#x02009;=&#x02009;0.05).</p><fig id="F3" position="float"><label>Figure 3</label><caption><p><bold>Survival analysis under FLO/FLP treatment in regards of CXCR4 expression in an observation period of 5&#x000a0;years. A</bold>. CXCR4 negative. <bold>B</bold>. CXCR4 positive.</p></caption><graphic xlink:href="1471-2407-14-476-3"/></fig></sec><sec><title>Patients older than 60&#x000a0;years</title><p>At this part of our study we performed an exploratory analysis examining whether VEGFR-3 and CXCR4 show the same predictive value for older patients.</p><p>In the post-hoc subgroup of patients older than 60&#x000a0;years at diagnosis, we found a significant benefit in overall survival for VEGFR-3 and CXCR4 positive patients when treated with FLP (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>A and B, p&#x02009;=&#x02009;0.002, p&#x02009;=&#x02009;0.021 respectively). No patient of this subgroup with negative VEGFR-3 expression status survived the first year after diagnosis of gastric cancer. However, similar findings were not observed when older patients with weak tumour expression of VEGFR-3 and CXCR4 were treated with FLO (data not shown).</p><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Survival analysis under FLP treatment for patients older than 60&#x000a0;years. A</bold>. VEGF-R3 and <bold>B</bold>. CXCR4 expression in an observation period of 5&#x000a0;years.</p></caption><graphic xlink:href="1471-2407-14-476-4"/></fig></sec><sec><title>Combination of the results for VEGFR-3 and CXCR4</title><p>Patients with a strong expression of VEGFR-3 and CXCR4 benefited in overall survival from the treatment with the cisplatin-containing FLP scheme (Figure&#x000a0;<xref ref-type="fig" rid="F5">5</xref>A, p&#x02009;=&#x02009;0.126). In contrast, patients with weak expression of CXCR4 and VEGFR-3 lived significantly longer with FLO (Figure&#x000a0;<xref ref-type="fig" rid="F5">5</xref>B, p&#x02009;=&#x02009;0.011).</p><fig id="F5" position="float"><label>Figure 5</label><caption><p><bold>Survival analysis under FLO/FLP treatment in an observation period of 5&#x000a0;years. A</bold>. VEGF-R3 and CXCR4 positive. <bold>B</bold>. VEGF-R3 and CXCR4 negative.</p></caption><graphic xlink:href="1471-2407-14-476-5"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>Seeking reliable markers to predict chemotherapeutic efficacy in advanced esophagogastric cancer, tumour tissues from 72 patients from the collective of the FLO vs. FLP phase III study of the AIO were tested for expression of VEGFR-3 and CXCR4. Both of these molecules have recently been associated with aggressive and metastatic esophagogastric cancer [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B26">26</xref>].</p><p>As previously described [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>], no significant difference between the therapeutic regimes FLO vs FLP was observed in terms of survival of the overall population over 5&#x000a0;years.</p><p>In our collective almost half of the specimens showed a strong positivity for VEGFR-3 (54%), whereas 36% of all tissue samples proved to be strongly positive for CXCR4 as assessed by immunohistochemistry. Similar findings have been reported previously in esophageal adenocarcinoma [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B33">33</xref>] as well as for adenocarcinoma of the stomach [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B34">34</xref>]. Taking into consideration that the majority of the CXCR4 and VEGFR-3 measurements, according to the literature, have been performed on tumour tissues after curative gastrectomy, we could expect an increase of the expression of these molecules in patients who are treated in a palliative setting.</p><p>In the present study there was a clear benefit in survival when the VEGFR-3 negative patients were treated with oxaliplatin instead of cisplatin. The stronger benefit in this category of patients was seen in the first 18&#x000a0;months of treatment. Conversely, patients with strong VEGFR-3 expression responded better under a cisplatin-containing regimen. Similar results have been reported by Ni et al. [<xref ref-type="bibr" rid="B35">35</xref>] who showed significantly longer overall survival when FLO was administered in patients with advanced gastric cancer and low VEGFR-3 serum levels. The median OS was 15.4&#x000a0;months whereas in our study it was 22&#x000a0;months. Ni et al. however, measured only soluble VEGFR-3, thus a direct comparison between these two studies cannot be made. Nevertheless, both of these studies indicate high VEGFR-3 expression is a poor prognostic marker in terms of survival for patients receiving FLO.</p><p>Although the correlation of VEGFR-3 expression and response to chemotherapy has been the focus of research in various forms of cancer [<xref ref-type="bibr" rid="B36">36</xref>-<xref ref-type="bibr" rid="B38">38</xref>], there are only limited data concerning gastric cancer [<xref ref-type="bibr" rid="B39">39</xref>,<xref ref-type="bibr" rid="B40">40</xref>]. We have previously shown the addition of the VEGFR-1-3 inhibitor, sunitinib to enhance the chemosensitivity of gastric cancer cell lines <italic>in vitro</italic>[<xref ref-type="bibr" rid="B39">39</xref>]. Our present results demonstrate a clear benefit of patients with strong VEGFR-3 expression in favour of FLP specifically when compared with patients with a low tumour VEGFR-3 expression (Figure&#x000a0;<xref ref-type="fig" rid="F2">2</xref>). In those patients older than 60&#x000a0;years the benefit of a cisplatin containing therapy was even greater in the VEGFR-3 positive group, as no patient in the VEGFR-3 negative subgroup receiving FLP survived the first year (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>A).</p><p>A possible explanation for the enhanced chemosensitivity of VEGFR-3 positive gastric cancer cells to cisplatin may be deduced by inhibition of the Notch pathway. Tamella and colleagues [<xref ref-type="bibr" rid="B9">9</xref>] revealed that VEGFR-3 upregulation in endothelial tip cells, caused by inhibition of the Notch signalling pathway, played a crucial role in sprouting angiogenesis in tumours. Since Notch inhibition has also been connected with the enhanced toxicity of cisplatin in colorectal cancer lines and nasopharyngeal adenocarcinoma [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B42">42</xref>], our results may indicate a similar pathophysiological mechanism for advanced esophagogastric cancer. The reason why oxaliplatin appeared to be less effective in VEGFR-3 positive patients remains unknown. However our data are consistent with those of Aleksic et al. [<xref ref-type="bibr" rid="B41">41</xref>], who noticed that several colorectal cancer lines showed no responsiveness to oxaliplatin, compared with cisplatin, when Notch signalling was blocked.</p><p>When CXCR4 expression levels on tumour tissues were measured similar results were observed. Patients with weak CXCR4 expression profited more from FLO whereas CXCR4 positive patients had a significantly longer 5&#x000a0;year overall survival under FLP (Figure&#x000a0;<xref ref-type="fig" rid="F3">3</xref>). This effect could also be clearly seen in patients older than 60&#x000a0;years with strong CXCR4 positivity as they showed a better response to FLP than the CXCR4 negative ones (Figure&#x000a0;<xref ref-type="fig" rid="F4">4</xref>B).</p><p>To date, the significance of CXCR4 as a potential predictive marker for chemotherapy in gastric cancer has been reported only in cellular models [<xref ref-type="bibr" rid="B43">43</xref>]. Xie et al. showed a correlation of CXCR4 mRNA levels in gastric cancer with docetaxel sensitivity, whereas the blockade of CXCR4 enhanced docetaxel toxicity. Nevertheless, there are no data that provide a possible explanation for the better responsiveness of CXCR4 positive esophagogastric cancer to cisplatin than to other platinum derives.</p><p>It is of great interest in relation to the connection of extracellular-signal related kinases (ERKs) with the stromal cell-derived factor 1 (SDF-1) mediated pathway. Similar to VEGFR-3 [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B44">44</xref>,<xref ref-type="bibr" rid="B45">45</xref>], the activation of CXCR4 by its natural ligand SDF-1 leads to phosphorylation and activation of multiple intracellular domains including ERKs [<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B49">49</xref>]. Since cisplatin relies on ERK activation for bioactivity in some cells [<xref ref-type="bibr" rid="B41">41</xref>,<xref ref-type="bibr" rid="B44">44</xref>], in contrast to oxaliplatin [<xref ref-type="bibr" rid="B50">50</xref>], this might explain the chemosensitivity of VEGFR-3 and CXCR4 positive esophagogastric adenocarcinoma to FLP and not to FLO.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>To the best of our knowledge this is the first comparative study of FLP and FLO in terms of VEGFR-3 and CXCR4 tumour expression. The list below shows the main findings and conclusions of our trial in accordance to the REMARK guidelines. The main limitation of our study is its size (n&#x02009;=&#x02009;72) and thus, its power is not very high. However, our results suggest a predictive value of these biomarkers concerning chemotherapy with FLP or FLO in advanced esophagogastric cancer. A trend of longer OS was observed when CXCR4 and VEGFR-3 positive patients were treated with FLP, whereas FLO proved to be more effective in CXCR4 and VEGFR-3 negative patients. Further studies are required in order to investigate the predictive value of VEGFR-3 and CXCR4 in terms of chemotherapeutic regimes in patients with advanced adenocarcinoma of the stomach and GEJ.</p><p>List of main steps and findings of the current study according to the REMARK guidelines</p><p>Introduction</p><p>1. VEGFR-3 and CXCR4 were the examined markers at this study. The objectives of the current study were to examine, whether VEGFR-3 and CXCR4 could have a predictive value in patients with advanced esophagogastric cancer under the treatment of FLO vs. FLO regime.</p><p>Materials and Methods</p><p>Patients</p><p>2. Patients with histologically confirmed locally advanced or metastatic adenocarcinoma of the stomach or the esophagogastric junction were eligible. Patients characteristics, inclusion and exclusion criteria have already been described before [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Specimen characteristics and assay methods</p><p>3. Paraffin-embedded tissue samples were obtained from patients with advanced esophagogastric cancer. The expression of VEGFR-3 and CXCR4 was analyzed by immunohistochemistry. Evaluation of staining was performed by two independent, blinded investigators.</p><p>Study design</p><p>4. This study is a retrospective translational analysis of a phase III trial in metastatic gastroesophageal adenocarcinoma. Patients were treated with fluorouracil, leucovorin plus either oxaliplatin or cisplatin as described before [<xref ref-type="bibr" rid="B7">7</xref>]. Main end point of the study was overall survival in relation to VEGFR-3/CXCR4 under palliative chemotherapy.</p><p>Statistical analysis methods</p><p>5. The staining was evaluated by intensity and the extent of the stained tumour area. These two classifications were added together and divided into the categories negative and positive. All statistical analyses were done by using SPSS statistical analysis software. The survival and univariate analysis were performed by using Kaplan-Meier method, log rank test, Pearson's Chi-2 test or Fisher's exact test.</p><p>Result</p><p>Data</p><p>6. The primary tumour location as well as the basic demographic characteristics of the patients who participated at the current trial is demonstrated in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>. There was an equal distribution of the patients in regards of treatment and positivity of markers.</p><p>Analysis and presentation</p><p>7. In the survival analysis, patients with strong expression of CXCR4 on their tumour tissues profited more in terms of overall survival under the treatment of FLP. Patients with negative VEGFR-3 and CXCR4 expression had a trend to live longer when treated with FLO. In an exploratory analysis of patients older than 60&#x000a0;years at diagnosis, there was a significant benefit in overall survival for patients with strong VEGFR-3 and CXCR4 expression when treated with FLP.</p><p>Discussion</p><p>8. CXCR4 positive patients profited in terms of OS from FLP, whereas FLO proved to be more effective in CXCR4 and VEGFR-3 negative patients. The main limitation of our study is its not very high power, due to the size of the examined tissues (n&#x02009;=&#x02009;72). However, our results suggest a predictive value of these biomarkers concerning chemotherapy with FLP or FLO in advanced esophagogastric cancer. Further studies are required in order to investigate the predictive value of VEGFR-3 and CXCR4 in terms of chemotherapeutic regimes in patients with advanced adenocarcinoma of the stomach and the gastroesophagic junction.</p></sec><sec><title>Abbreviations</title><p>VEGFR-3: Vascular endothelial growth factor receptor 3; CXCR4: CXC-chemokine receptor type 4; GEJ: Gastroesophageal junction; FLO: Oxaliplatin/leucovorin/5-FU; FLP: Cisplatin/leucovorin/5-FU; AIO: Arbeitsgemeinschaft Internistische Onkologie.</p></sec><sec><title>Competing interests</title><p>After the last recruited patient M Moehler and S. -E. Al-Batran received honoraria for presentations in satellite symposia by Sanofi-Aventis. The rest of the authors have no competing interests to declare.</p></sec><sec><title>Authors&#x02019; contributions</title><p>TT: acquisition of data, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript, statistical analysis, AM: acquisition of data, analysis and interpretation of data, critical revision of the manuscript, statistical analysis. SEA: study concept and design, patients' recruitment, JK: acquisition of data, analysis and interpretation of data. CP: patient's recruitment, critical revision of the manuscript, KS: patient's recruitment, technical or material support. AS: acquisition of data, RH: patient's recruitment, technical or material support, HS: patient's recruitment, technical or material support, NH: patient's recruitment, technical or material support. PRG: critical revision of the manuscript, administrative support, study supervision. MM: study concept and design, drafting of the manuscript, critical revision of the manuscript, study supervision. All the authors critically reviewed the paper. All authors read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/14/476/prepub">http://www.biomedcentral.com/1471-2407/14/476/prepub</ext-link></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p>Comparative patient characteristics between the translational study and the overall phase III trial.</p></caption><media xlink:href="1471-2407-14-476-S1.doc"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>The authors are grateful to all investigators and patients who participated in the trial. We would like to thank all the centres that contributed to the patients' recruitment. We thank Monika Linnig for the technical assistance and the excellent collaboration. The results described in this manuscript are part of the MD thesis of Mr. Janis Kany. The authors also thank the IMBEI for their assistance with the statistical analyses. The manuscript was reviewed by all authors.</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><year>2011</year><volume>61</volume><issue>2</issue><fpage>69</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Unverzagt</surname><given-names>S</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Kleber</surname><given-names>G</given-names></name><name><surname>Grothey</surname><given-names>A</given-names></name><name><surname>Haerting</surname><given-names>J</given-names></name><name><surname>Fleig</surname><given-names>WE</given-names></name><article-title>Chemotherapy for advanced gastric cancer</article-title><source>Cochrane Database Syst Rev</source><year>2010</year><volume>3</volume><comment>CD004064</comment></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>NK</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Heo</surname><given-names>DS</given-names></name><name><surname>Suh</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Park</surname><given-names>KC</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Kim</surname><given-names>HT</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kang</surname><given-names>WK</given-names></name><name><surname>Suh</surname><given-names>CI</given-names></name><name><surname>Bang</surname><given-names>YJ</given-names></name><article-title>A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer</article-title><source>Cancer</source><year>1993</year><volume>71</volume><issue>12</issue><fpage>3813</fpage><lpage>3818</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19930615)71:12&#x0003c;3813::AID-CNCR2820711205&#x0003e;3.0.CO;2-5</pub-id><pub-id pub-id-type="pmid">8508349</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Vanhoefer</surname><given-names>U</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Wilke</surname><given-names>H</given-names></name><name><surname>Ducreux</surname><given-names>MP</given-names></name><name><surname>Lacave</surname><given-names>AJ</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Planker</surname><given-names>M</given-names></name><name><surname>Santos</surname><given-names>JG</given-names></name><name><surname>Piedbois</surname><given-names>P</given-names></name><name><surname>Paillot</surname><given-names>B</given-names></name><name><surname>Bodenstein</surname><given-names>H</given-names></name><name><surname>Schmoll</surname><given-names>HJ</given-names></name><name><surname>Bleiberg</surname><given-names>H</given-names></name><name><surname>Nordlinger</surname><given-names>B</given-names></name><name><surname>Couvreur</surname><given-names>ML</given-names></name><name><surname>Baron</surname><given-names>B</given-names></name><name><surname>Wils</surname><given-names>JA</given-names></name><article-title>Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><issue>14</issue><fpage>2648</fpage><lpage>2657</lpage><pub-id pub-id-type="pmid">10894863</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Scarffe</surname><given-names>JH</given-names></name><name><surname>Harper</surname><given-names>P</given-names></name><name><surname>Norman</surname><given-names>A</given-names></name><name><surname>Joffe</surname><given-names>JK</given-names></name><name><surname>Hughes</surname><given-names>M</given-names></name><name><surname>Mansi</surname><given-names>J</given-names></name><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>A</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Hickish</surname><given-names>T</given-names></name><name><surname>O'Brien</surname><given-names>M</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Watson</surname><given-names>M</given-names></name><name><surname>Underhill</surname><given-names>C</given-names></name><name><surname>Wardley</surname><given-names>A</given-names></name><name><surname>Meehan</surname><given-names>M</given-names></name><article-title>Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer</article-title><source>J Clin Oncol</source><year>1997</year><volume>15</volume><issue>1</issue><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">8996151</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Cunningham</surname><given-names>D</given-names></name><name><surname>Starling</surname><given-names>N</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Iveson</surname><given-names>T</given-names></name><name><surname>Nicolson</surname><given-names>M</given-names></name><name><surname>Coxon</surname><given-names>F</given-names></name><name><surname>Middleton</surname><given-names>G</given-names></name><name><surname>Daniel</surname><given-names>F</given-names></name><name><surname>Oates</surname><given-names>J</given-names></name><name><surname>Norman</surname><given-names>AR</given-names></name><article-title>Capecitabine and oxaliplatin for advanced esophagogastric cancer</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><issue>1</issue><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa073149</pub-id><pub-id pub-id-type="pmid">18172173</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Probst</surname><given-names>S</given-names></name><name><surname>Schmalenberg</surname><given-names>H</given-names></name><name><surname>Hollerbach</surname><given-names>S</given-names></name><name><surname>Hofheinz</surname><given-names>R</given-names></name><name><surname>Rethwisch</surname><given-names>V</given-names></name><name><surname>Seipelt</surname><given-names>G</given-names></name><name><surname>Homann</surname><given-names>N</given-names></name><name><surname>Wilhelm</surname><given-names>G</given-names></name><name><surname>Schuch</surname><given-names>G</given-names></name><name><surname>Stoehlmacher</surname><given-names>J</given-names></name><name><surname>Derigs</surname><given-names>HG</given-names></name><name><surname>Hegewisch-Becker</surname><given-names>S</given-names></name><name><surname>Grossmann</surname><given-names>J</given-names></name><name><surname>Pauligk</surname><given-names>C</given-names></name><name><surname>Atmaca</surname><given-names>A</given-names></name><name><surname>Bokemeyer</surname><given-names>C</given-names></name><name><surname>Knuth</surname><given-names>A</given-names></name><name><surname>Jager</surname><given-names>E</given-names></name><article-title>Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>9</issue><fpage>1435</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.13.9378</pub-id><pub-id pub-id-type="pmid">18349393</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Mao</surname><given-names>F</given-names></name><article-title>Combination of circulating CXCR4 and Bmi-1 mRNA in plasma: a potential novel tumor marker for gastric cancer</article-title><source>Mol Med Report</source><year>2009</year><volume>2</volume><issue>5</issue><fpage>765</fpage><lpage>771</lpage></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Tammela</surname><given-names>T</given-names></name><name><surname>Zarkada</surname><given-names>G</given-names></name><name><surname>Wallgard</surname><given-names>E</given-names></name><name><surname>Murtomaki</surname><given-names>A</given-names></name><name><surname>Suchting</surname><given-names>S</given-names></name><name><surname>Wirzenius</surname><given-names>M</given-names></name><name><surname>Waltari</surname><given-names>M</given-names></name><name><surname>Hellstrom</surname><given-names>M</given-names></name><name><surname>Schomber</surname><given-names>T</given-names></name><name><surname>Peltonen</surname><given-names>R</given-names></name><name><surname>Freitas</surname><given-names>C</given-names></name><name><surname>Duarte</surname><given-names>A</given-names></name><name><surname>Isoniemi</surname><given-names>H</given-names></name><name><surname>Laakkonen</surname><given-names>P</given-names></name><name><surname>Christofori</surname><given-names>G</given-names></name><name><surname>Yla-Herttuala</surname><given-names>S</given-names></name><name><surname>Shibuya</surname><given-names>M</given-names></name><name><surname>Pytowski</surname><given-names>B</given-names></name><name><surname>Eichmann</surname><given-names>A</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><article-title>Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation</article-title><source>Nature</source><year>2008</year><volume>454</volume><issue>7204</issue><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1038/nature07083</pub-id><pub-id pub-id-type="pmid">18594512</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Laakkonen</surname><given-names>P</given-names></name><name><surname>Waltari</surname><given-names>M</given-names></name><name><surname>Holopainen</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Pytowski</surname><given-names>B</given-names></name><name><surname>Steiner</surname><given-names>P</given-names></name><name><surname>Hicklin</surname><given-names>D</given-names></name><name><surname>Persaud</surname><given-names>K</given-names></name><name><surname>Tonra</surname><given-names>JR</given-names></name><name><surname>Witte</surname><given-names>L</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><article-title>Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth</article-title><source>Cancer Res</source><year>2007</year><volume>67</volume><issue>2</issue><fpage>593</fpage><lpage>599</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-3567</pub-id><pub-id pub-id-type="pmid">17234768</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Han</surname><given-names>FH</given-names></name><name><surname>Li</surname><given-names>HM</given-names></name><name><surname>Zheng</surname><given-names>DH</given-names></name><name><surname>He</surname><given-names>YL</given-names></name><name><surname>Zhan</surname><given-names>WH</given-names></name><article-title>The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma</article-title><source>Eur J Surg Oncol</source><year>2010</year><volume>36</volume><issue>12</issue><fpage>1172</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1016/j.ejso.2010.09.002</pub-id><pub-id pub-id-type="pmid">20888167</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Choi</surname><given-names>JH</given-names></name><name><surname>Oh</surname><given-names>YH</given-names></name><name><surname>Park</surname><given-names>YW</given-names></name><name><surname>Baik</surname><given-names>HK</given-names></name><name><surname>Lee</surname><given-names>YY</given-names></name><name><surname>Kim</surname><given-names>IS</given-names></name><article-title>Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma</article-title><source>J Korean Med Sci</source><year>2008</year><volume>23</volume><issue>4</issue><fpage>592</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.3346/jkms.2008.23.4.592</pub-id><pub-id pub-id-type="pmid">18756043</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Sung</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YW</given-names></name><name><surname>Park</surname><given-names>YK</given-names></name><article-title>Vascular endothelial growth factor receptor-3 is a favorable prognostic factor in advanced gastric carcinoma</article-title><source>Oncol Rep</source><year>2008</year><volume>19</volume><issue>4</issue><fpage>939</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">18357379</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Juttner</surname><given-names>S</given-names></name><name><surname>Wissmann</surname><given-names>C</given-names></name><name><surname>Jons</surname><given-names>T</given-names></name><name><surname>Vieth</surname><given-names>M</given-names></name><name><surname>Hertel</surname><given-names>J</given-names></name><name><surname>Gretschel</surname><given-names>S</given-names></name><name><surname>Schlag</surname><given-names>PM</given-names></name><name><surname>Kemmner</surname><given-names>W</given-names></name><name><surname>Hocker</surname><given-names>M</given-names></name><article-title>Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>2</issue><fpage>228</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">16344322</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>BC</given-names></name><name><surname>Wang</surname><given-names>ZJ</given-names></name><name><surname>Mao</surname><given-names>WZ</given-names></name><name><surname>Ma</surname><given-names>HC</given-names></name><name><surname>Han</surname><given-names>JG</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>HM</given-names></name><article-title>CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><issue>19</issue><fpage>2389</fpage><lpage>2396</lpage><pub-id pub-id-type="doi">10.3748/wjg.v17.i19.2389</pub-id><pub-id pub-id-type="pmid">21633638</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Ying</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><article-title>The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis</article-title><source>Med Oncol</source><year>2012</year><volume>29</volume><issue>3</issue><fpage>1716</fpage><lpage>1722</lpage><pub-id pub-id-type="doi">10.1007/s12032-011-9990-0</pub-id><pub-id pub-id-type="pmid">21630055</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><name><surname>Heinrich</surname><given-names>C</given-names></name><name><surname>Wehler</surname><given-names>T</given-names></name><name><surname>Frerichs</surname><given-names>K</given-names></name><name><surname>Drescher</surname><given-names>D</given-names></name><name><surname>von Langsdorff</surname><given-names>C</given-names></name><name><surname>Domeyer</surname><given-names>M</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Junginger</surname><given-names>T</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><article-title>Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma</article-title><source>BMC Cancer</source><year>2006</year><volume>6</volume><fpage>290</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-6-290</pub-id><pub-id pub-id-type="pmid">17176471</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="journal"><name><surname>Ozmen</surname><given-names>F</given-names></name><name><surname>Ozmen</surname><given-names>MM</given-names></name><name><surname>Ozdemir</surname><given-names>E</given-names></name><name><surname>Moran</surname><given-names>M</given-names></name><name><surname>Seckin</surname><given-names>S</given-names></name><name><surname>Guc</surname><given-names>D</given-names></name><name><surname>Karaagaoglu</surname><given-names>E</given-names></name><name><surname>Kansu</surname><given-names>E</given-names></name><article-title>Relationship between LYVE-1, VEGFR-3 and CD44 gene expressions and lymphatic metastasis in gastric cancer</article-title><source>World J Gastroenterol</source><year>2011</year><volume>17</volume><issue>27</issue><fpage>3220</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">21912471</pub-id></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><name><surname>Qin</surname><given-names>XJ</given-names></name><name><surname>Dai</surname><given-names>DJ</given-names></name><name><surname>Gao</surname><given-names>ZG</given-names></name><name><surname>Huan</surname><given-names>JL</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><article-title>Effect of lentivirus-mediated shRNA targeting VEGFR-3 on proliferation, apoptosis and invasion of gastric cancer cells</article-title><source>Int J Mol Med</source><year>2011</year><volume>28</volume><issue>5</issue><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="pmid">21805024</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Shimizu</surname><given-names>K</given-names></name><name><surname>Kubo</surname><given-names>H</given-names></name><name><surname>Yamaguchi</surname><given-names>K</given-names></name><name><surname>Kawashima</surname><given-names>K</given-names></name><name><surname>Ueda</surname><given-names>Y</given-names></name><name><surname>Matsuo</surname><given-names>K</given-names></name><name><surname>Awane</surname><given-names>M</given-names></name><name><surname>Shimahara</surname><given-names>Y</given-names></name><name><surname>Takabayashi</surname><given-names>A</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name><article-title>Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer</article-title><source>Cancer Sci</source><year>2004</year><volume>95</volume><issue>4</issue><fpage>328</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1111/j.1349-7006.2004.tb03211.x</pub-id><pub-id pub-id-type="pmid">15072591</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Yonemura</surname><given-names>Y</given-names></name><name><surname>Fushida</surname><given-names>S</given-names></name><name><surname>Bando</surname><given-names>E</given-names></name><name><surname>Kinoshita</surname><given-names>K</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Endo</surname><given-names>Y</given-names></name><name><surname>Sugiyama</surname><given-names>K</given-names></name><name><surname>Partanen</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>H</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><article-title>Lymphangiogenesis and the vascular endothelial growth factor receptor (VEGFR)-3 in gastric cancer</article-title><source>Eur J Cancer</source><year>2001</year><volume>37</volume><issue>7</issue><fpage>918</fpage><lpage>923</lpage><pub-id pub-id-type="doi">10.1016/S0959-8049(01)00015-6</pub-id><pub-id pub-id-type="pmid">11313181</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Hashimoto</surname><given-names>I</given-names></name><name><surname>Yasumoto</surname><given-names>K</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name><article-title>Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer</article-title><source>Front Biosci (Schol Ed)</source><year>2012</year><volume>4</volume><fpage>269</fpage><lpage>276</lpage><pub-id pub-id-type="pmid">22202059</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><name><surname>Iwasa</surname><given-names>S</given-names></name><name><surname>Yanagawa</surname><given-names>T</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Katoh</surname><given-names>R</given-names></name><article-title>Expression of CXCR4 and its ligand SDF-1 in intestinal-type gastric cancer is associated with lymph node and liver metastasis</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><issue>11</issue><fpage>4751</fpage><lpage>4758</lpage><pub-id pub-id-type="pmid">20032431</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><name><surname>Arigami</surname><given-names>T</given-names></name><name><surname>Natsugoe</surname><given-names>S</given-names></name><name><surname>Uenosono</surname><given-names>Y</given-names></name><name><surname>Yanagita</surname><given-names>S</given-names></name><name><surname>Arima</surname><given-names>H</given-names></name><name><surname>Hirata</surname><given-names>M</given-names></name><name><surname>Ishigami</surname><given-names>S</given-names></name><name><surname>Aikou</surname><given-names>T</given-names></name><article-title>CCR7 and CXCR4 expression predicts lymph node status including micrometastasis in gastric cancer</article-title><source>Int J Oncol</source><year>2009</year><volume>35</volume><issue>1</issue><fpage>19</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">19513547</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><name><surname>Yasumoto</surname><given-names>K</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Kawashima</surname><given-names>A</given-names></name><name><surname>Saitoh</surname><given-names>Y</given-names></name><name><surname>Arita</surname><given-names>Y</given-names></name><name><surname>Shinohara</surname><given-names>K</given-names></name><name><surname>Minami</surname><given-names>T</given-names></name><name><surname>Nakayama</surname><given-names>T</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Yoshie</surname><given-names>O</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name><article-title>Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><issue>4</issue><fpage>2181</fpage><lpage>2187</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-3393</pub-id><pub-id pub-id-type="pmid">16489019</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><name><surname>Hashimoto</surname><given-names>I</given-names></name><name><surname>Koizumi</surname><given-names>K</given-names></name><name><surname>Tatematsu</surname><given-names>M</given-names></name><name><surname>Minami</surname><given-names>T</given-names></name><name><surname>Cho</surname><given-names>S</given-names></name><name><surname>Takeno</surname><given-names>N</given-names></name><name><surname>Nakashima</surname><given-names>A</given-names></name><name><surname>Sakurai</surname><given-names>H</given-names></name><name><surname>Saito</surname><given-names>S</given-names></name><name><surname>Tsukada</surname><given-names>K</given-names></name><name><surname>Saiki</surname><given-names>I</given-names></name><article-title>Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells</article-title><source>Eur J Cancer</source><year>2008</year><volume>44</volume><issue>7</issue><fpage>1022</fpage><lpage>1029</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2008.02.043</pub-id><pub-id pub-id-type="pmid">18375114</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><name><surname>Shah</surname><given-names>MA</given-names></name><name><surname>Ramanathan</surname><given-names>RK</given-names></name><name><surname>Ilson</surname><given-names>DH</given-names></name><name><surname>Levnor</surname><given-names>A</given-names></name><name><surname>D'Adamo</surname><given-names>D</given-names></name><name><surname>O'Reilly</surname><given-names>E</given-names></name><name><surname>Tse</surname><given-names>A</given-names></name><name><surname>Trocola</surname><given-names>R</given-names></name><name><surname>Schwartz</surname><given-names>L</given-names></name><name><surname>Capanu</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>GK</given-names></name><name><surname>Kelsen</surname><given-names>DP</given-names></name><article-title>Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><issue>33</issue><fpage>5201</fpage><lpage>5206</lpage><pub-id pub-id-type="doi">10.1200/JCO.2006.08.0887</pub-id><pub-id pub-id-type="pmid">17114652</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><name><surname>Okines</surname><given-names>AF</given-names></name><name><surname>Langley</surname><given-names>RE</given-names></name><name><surname>Thompson</surname><given-names>LC</given-names></name><name><surname>Stenning</surname><given-names>SP</given-names></name><name><surname>Stevenson</surname><given-names>L</given-names></name><name><surname>Falk</surname><given-names>S</given-names></name><name><surname>Seymour</surname><given-names>M</given-names></name><name><surname>Coxon</surname><given-names>F</given-names></name><name><surname>Middleton</surname><given-names>GW</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>L</given-names></name><name><surname>Slater</surname><given-names>S</given-names></name><name><surname>Waters</surname><given-names>J</given-names></name><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Hall</surname><given-names>M</given-names></name><name><surname>Iveson</surname><given-names>TJ</given-names></name><name><surname>Petty</surname><given-names>RD</given-names></name><name><surname>Plummer</surname><given-names>C</given-names></name><name><surname>Allum</surname><given-names>WH</given-names></name><name><surname>Blazeby</surname><given-names>JM</given-names></name><name><surname>Griffin</surname><given-names>M</given-names></name><name><surname>Cunningham</surname><given-names>D</given-names></name><article-title>Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report</article-title><source>Ann Oncol</source><year>2013</year><volume>24</volume><issue>3</issue><fpage>702</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1093/annonc/mds533</pub-id><pub-id pub-id-type="pmid">23108952</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><name><surname>Ohtsu</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>MA</given-names></name><name><surname>Van Cutsem</surname><given-names>E</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name><name><surname>Sawaki</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>SR</given-names></name><name><surname>Lim</surname><given-names>HY</given-names></name><name><surname>Yamada</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Langer</surname><given-names>B</given-names></name><name><surname>Starnawski</surname><given-names>M</given-names></name><name><surname>Kang</surname><given-names>YK</given-names></name><article-title>Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study</article-title><source>J Clin Oncol</source><year>2011</year><volume>29</volume><issue>30</issue><fpage>3968</fpage><lpage>3976</lpage><pub-id pub-id-type="doi">10.1200/JCO.2011.36.2236</pub-id><pub-id pub-id-type="pmid">21844504</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Seufferlein</surname><given-names>T</given-names></name><name><surname>Kubicka</surname><given-names>S</given-names></name><name><surname>Geissler</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>S</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Kanzler</surname><given-names>S</given-names></name><article-title>Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study</article-title><source>Ann Oncol</source><year>2011</year><volume>22</volume><issue>6</issue><fpage>1358</fpage><lpage>1366</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdq591</pub-id><pub-id pub-id-type="pmid">21119032</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="journal"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>JT</given-names></name><name><surname>Ebert</surname><given-names>MP</given-names></name><name><surname>Al-Batran</surname><given-names>SE</given-names></name><name><surname>Reimer</surname><given-names>P</given-names></name><name><surname>Weihrauch</surname><given-names>M</given-names></name><name><surname>Lordick</surname><given-names>F</given-names></name><name><surname>Trarbach</surname><given-names>T</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Kabisch</surname><given-names>M</given-names></name><name><surname>Wachtlin</surname><given-names>D</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><article-title>An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer</article-title><source>Eur J Cancer</source><year>2011</year><volume>47</volume><issue>10</issue><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2011.04.006</pub-id><pub-id pub-id-type="pmid">21561763</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><name><surname>Wehler</surname><given-names>T</given-names></name><name><surname>Wolfert</surname><given-names>F</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Herr</surname><given-names>W</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Seifert</surname><given-names>JK</given-names></name><name><surname>Adwan</surname><given-names>H</given-names></name><name><surname>Berger</surname><given-names>MR</given-names></name><name><surname>Junginger</surname><given-names>T</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><article-title>Strong expression of chemokine receptor CXCR4 by pancreatic cancer correlates with advanced disease</article-title><source>Oncol Rep</source><year>2006</year><volume>16</volume><issue>6</issue><fpage>1159</fpage><lpage>1164</lpage><pub-id pub-id-type="pmid">17089032</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Frerichs</surname><given-names>K</given-names></name><name><surname>Drescher</surname><given-names>D</given-names></name><name><surname>Trinh</surname><given-names>TT</given-names></name><name><surname>Duenschede</surname><given-names>F</given-names></name><name><surname>Borschitz</surname><given-names>T</given-names></name><name><surname>Schimanski</surname><given-names>K</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Herzer</surname><given-names>K</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Junginger</surname><given-names>T</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><article-title>Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer</article-title><source>Oncol Rep</source><year>2008</year><volume>20</volume><issue>4</issue><fpage>845</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">18813825</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><name><surname>Drescher</surname><given-names>D</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Frerichs</surname><given-names>K</given-names></name><name><surname>Muller</surname><given-names>A</given-names></name><name><surname>Dunschede</surname><given-names>F</given-names></name><name><surname>Borschitz</surname><given-names>T</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Holtmann</surname><given-names>M</given-names></name><name><surname>Wehler</surname><given-names>T</given-names></name><name><surname>Teufel</surname><given-names>A</given-names></name><name><surname>Herzer</surname><given-names>K</given-names></name><name><surname>Fischer</surname><given-names>T</given-names></name><name><surname>Berger</surname><given-names>MR</given-names></name><name><surname>Junginger</surname><given-names>T</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><article-title>Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma&#x02013;a rationale for a molecular targeting strategy?</article-title><source>World J Gastroenterol</source><year>2007</year><volume>13</volume><issue>26</issue><fpage>3605</fpage><lpage>3609</lpage><pub-id pub-id-type="pmid">17659711</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><name><surname>Ni</surname><given-names>XF</given-names></name><name><surname>Wu</surname><given-names>CP</given-names></name><name><surname>Jiang</surname><given-names>JT</given-names></name><article-title>Serum VEGFR-3 and survival of advanced gastric cancer patients treated with FOLFOX</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><issue>17</issue><fpage>2163</fpage><lpage>2169</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i17.2163</pub-id><pub-id pub-id-type="pmid">20440858</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><name><surname>DePrimo</surname><given-names>SE</given-names></name><name><surname>Bello</surname><given-names>C</given-names></name><article-title>Surrogate biomarkers in evaluating response to anti-angiogenic agents: focus on sunitinib</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><issue>Suppl 10</issue><fpage>11</fpage><lpage>19</lpage></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Michaelson</surname><given-names>MD</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Hutson</surname><given-names>TE</given-names></name><name><surname>Margolin</surname><given-names>K</given-names></name><name><surname>Harmon</surname><given-names>CS</given-names></name><name><surname>DePrimo</surname><given-names>SE</given-names></name><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>George</surname><given-names>DJ</given-names></name><article-title>Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>22</issue><fpage>3743</fpage><lpage>3748</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.15.5416</pub-id><pub-id pub-id-type="pmid">18669461</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Frings</surname><given-names>C</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><name><surname>Biesterfeld</surname><given-names>S</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Holtmann</surname><given-names>MH</given-names></name><article-title>VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><issue>26</issue><fpage>4156</fpage><lpage>4167</lpage><pub-id pub-id-type="doi">10.3748/wjg.14.4156</pub-id><pub-id pub-id-type="pmid">18636661</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><name><surname>Lyros</surname><given-names>O</given-names></name><name><surname>Mueller</surname><given-names>A</given-names></name><name><surname>Heidel</surname><given-names>F</given-names></name><name><surname>Schimanski</surname><given-names>CC</given-names></name><name><surname>Gockel</surname><given-names>I</given-names></name><name><surname>Galle</surname><given-names>PR</given-names></name><name><surname>Lang</surname><given-names>H</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><article-title>Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways</article-title><source>Int J Cancer</source><year>2010</year><volume>127</volume><issue>5</issue><fpage>1197</fpage><lpage>1208</lpage><pub-id pub-id-type="pmid">20039326</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Cai</surname><given-names>D</given-names></name><article-title>A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer</article-title><source>Hepatogastroenterology</source><year>2011</year><volume>58</volume><issue>109</issue><fpage>1425</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.5754/hge10749</pub-id><pub-id pub-id-type="pmid">21937420</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><name><surname>Aleksic</surname><given-names>T</given-names></name><name><surname>Feller</surname><given-names>SM</given-names></name><article-title>Gamma-secretase inhibition combined with platinum compounds enhances cell death in a large subset of colorectal cancer cells</article-title><source>Cell Commun Signal</source><year>2008</year><volume>6</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/1478-811X-6-8</pub-id><pub-id pub-id-type="pmid">18950493</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><name><surname>Man</surname><given-names>CH</given-names></name><name><surname>Wei-Man Lun</surname><given-names>S</given-names></name><name><surname>Wai-Ying Hui</surname><given-names>J</given-names></name><name><surname>To</surname><given-names>KF</given-names></name><name><surname>Choy</surname><given-names>KW</given-names></name><name><surname>Wing-Hung Chan</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>C</given-names></name><name><surname>Tin-Yun Chung</surname><given-names>G</given-names></name><name><surname>Tsao</surname><given-names>SW</given-names></name><name><surname>Tak-Chun Yip</surname><given-names>T</given-names></name><name><surname>Busson</surname><given-names>P</given-names></name><name><surname>Lo</surname><given-names>KW</given-names></name><article-title>Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma</article-title><source>J Pathol</source><year>2012</year><volume>226</volume><issue>3</issue><fpage>471</fpage><lpage>481</lpage><pub-id pub-id-type="doi">10.1002/path.2997</pub-id><pub-id pub-id-type="pmid">22009689</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Qian</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><article-title>CXCR4, a potential predictive marker for docetaxel sensitivity in gastric cancer</article-title><source>Anticancer Res</source><year>2010</year><volume>30</volume><issue>6</issue><fpage>2209</fpage><lpage>2216</lpage><pub-id pub-id-type="pmid">20651371</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><name><surname>Persons</surname><given-names>DL</given-names></name><name><surname>Yazlovitskaya</surname><given-names>EM</given-names></name><name><surname>Pelling</surname><given-names>JC</given-names></name><article-title>Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin</article-title><source>J Biol Chem</source><year>2000</year><volume>275</volume><issue>46</issue><fpage>35778</fpage><lpage>35785</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004267200</pub-id><pub-id pub-id-type="pmid">10958792</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><name><surname>Makinen</surname><given-names>T</given-names></name><name><surname>Veikkola</surname><given-names>T</given-names></name><name><surname>Mustjoki</surname><given-names>S</given-names></name><name><surname>Karpanen</surname><given-names>T</given-names></name><name><surname>Catimel</surname><given-names>B</given-names></name><name><surname>Nice</surname><given-names>EC</given-names></name><name><surname>Wise</surname><given-names>L</given-names></name><name><surname>Mercer</surname><given-names>A</given-names></name><name><surname>Kowalski</surname><given-names>H</given-names></name><name><surname>Kerjaschki</surname><given-names>D</given-names></name><name><surname>Stacker</surname><given-names>SA</given-names></name><name><surname>Achen</surname><given-names>MG</given-names></name><name><surname>Alitalo</surname><given-names>K</given-names></name><article-title>Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3</article-title><source>EMBO J</source><year>2001</year><volume>20</volume><issue>17</issue><fpage>4762</fpage><lpage>4773</lpage><pub-id pub-id-type="doi">10.1093/emboj/20.17.4762</pub-id><pub-id pub-id-type="pmid">11532940</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><name><surname>Roland</surname><given-names>J</given-names></name><name><surname>Murphy</surname><given-names>BJ</given-names></name><name><surname>Ahr</surname><given-names>B</given-names></name><name><surname>Robert-Hebmann</surname><given-names>V</given-names></name><name><surname>Delauzun</surname><given-names>V</given-names></name><name><surname>Nye</surname><given-names>KE</given-names></name><name><surname>Devaux</surname><given-names>C</given-names></name><name><surname>Biard-Piechaczyk</surname><given-names>M</given-names></name><article-title>Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling</article-title><source>Blood</source><year>2003</year><volume>101</volume><issue>2</issue><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-03-0978</pub-id><pub-id pub-id-type="pmid">12393663</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><name><surname>Ganju</surname><given-names>RK</given-names></name><name><surname>Brubaker</surname><given-names>SA</given-names></name><name><surname>Meyer</surname><given-names>J</given-names></name><name><surname>Dutt</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>S</given-names></name><name><surname>Newman</surname><given-names>W</given-names></name><name><surname>Groopman</surname><given-names>JE</given-names></name><article-title>The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways</article-title><source>J Biol Chem</source><year>1998</year><volume>273</volume><issue>36</issue><fpage>23169</fpage><lpage>23175</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.36.23169</pub-id><pub-id pub-id-type="pmid">9722546</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>JF</given-names></name><name><surname>Park</surname><given-names>IW</given-names></name><name><surname>Groopman</surname><given-names>JE</given-names></name><article-title>Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: roles of phosphoinositide-3 kinase and protein kinase C</article-title><source>Blood</source><year>2000</year><volume>95</volume><issue>8</issue><fpage>2505</fpage><lpage>2513</lpage><pub-id pub-id-type="pmid">10753828</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="journal"><name><surname>Vila-Coro</surname><given-names>AJ</given-names></name><name><surname>Rodriguez-Frade</surname><given-names>JM</given-names></name><name><surname>Martin De Ana</surname><given-names>A</given-names></name><name><surname>Moreno-Ortiz</surname><given-names>MC</given-names></name><name><surname>Martinez</surname><given-names>AC</given-names></name><name><surname>Mellado</surname><given-names>M</given-names></name><article-title>The chemokine SDF-1alpha triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway</article-title><source>FASEB J</source><year>1999</year><volume>13</volume><issue>13</issue><fpage>1699</fpage><lpage>1710</lpage><pub-id pub-id-type="pmid">10506573</pub-id></mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><name><surname>Rakitina</surname><given-names>TV</given-names></name><name><surname>Vasilevskaya</surname><given-names>IA</given-names></name><name><surname>O'Dwyer</surname><given-names>PJ</given-names></name><article-title>Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor kappaB signaling</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><issue>24</issue><fpage>8600</fpage><lpage>8605</lpage><pub-id pub-id-type="pmid">14695170</pub-id></mixed-citation></ref></ref-list></back></article>